Journal of Peking University(Health Sciences) ›› 2019, Vol. 51 ›› Issue (4): 628-631. doi: 10.19723/j.issn.1671-167X.2019.04.005

Previous Articles     Next Articles

Clinicopathologic features and prognostic analyses of locally recurrent renal cell carcinoma patients after initial surgery

Qi TANG,Rong-cheng LIN,Lin YAO,Zheng ZHANG,Han HAO,Cui-jian ZHANG,Lin CAI,Xue-song LI,Zhi-song HE(),Li-qun ZHOU()   

  1. Department of Urology, Peking University First Hospital; Institute of Urology, Peking University, Beijing 100034, China
  • Received:2019-03-06 Online:2019-08-18 Published:2019-09-03
  • Contact: Zhi-song HE,Li-qun ZHOU E-mail:wyj7074@sohu.com;zhoulqmail@china.com

RICH HTML

  

Abstract:

Objective: To evaluate the clinicopathologic features and potential prognostic predictors of locally recurrent renal cell carcinoma patients after initial surgery.Methods: Authors retrospectively analyzed data extracted from 81 patients who were treated for postoperative locally recurrence of renal cell carcinoma from January 2006 to June 2016 in the Department of Urology, Peking University First Hospital. Postoperative locally recurrence of renal cell carcinoma was defined as disease recurring in the remnant kidney, renal fossa, adjacent abdomen, ipsilateral adrenal and retroperitoneal lymph nodes.Results: In the study, 81 patients were finally included, of whom 43 were initially treated in our hospital and 38 were initially treat in other centers. Partial nephrectomy (PN) was performed for 38 cases (26 in our hospital and 12 in other hospitals) as initial treatment and radical nephrectomy (RN) was conducted for the remnant 43 cases (17 in our hospital and 26 in other hospitals). Overall median recurrence time was 26 months (range: 3-164 months), in which 26 months (range: 3-55 months) for PN cases and 30 months (range: 4-164 months) for RN cases (P=0.009). Sixty-nine patients had single site recurrence, including remnant kidney (n=29), renal fossa (n=20), abdomen (n=4), ipsilateral lymph nodes (n=5), ipsilateral adrenal (n=11), while 12 patients had multiple sites recurrence. Seventy-eight patients were managed by complete surgical resection, while three patients were managed by radiofrequency ablation. Postoperative pathological diagnoses included clear cell carcinoma (n=72), papi-llary renal cell carcinoma (n=8, 7 cases with type 1, 1 case with type 2) and Xp11 translocation/TFE3 gene fusion renal cell carcinoma (n=1). Complete pathologic information of the initial surgery could be extracted from 43 patients who were initially treated in our hospital. Seventeen patients with initial radical nephrectomy were staged as T1a (n=4), T1b (n=2), T2a (n=1), T3a (n=8), and T3b (n=2). Twenty-six patients with initial partial nephrectomy were staged as T1a (n=18), T1b (n=7), and T3a (n=1). For PN cohort, the patients with T1a stage disease had longer median recurrence time than those with beyond T1a stage disease, and the difference was significant (29 months vs. 18 months, P=0.041). At the end of the follow-up, 58 patients were alive, 4 died and 19 lost the follow-up. Overall, 3-year and 5-year disease free survival rates were 81.9%, and 53.6%, respectively.Conclusion: The present research reported a large-scale single central experience of locally recurrent renal cell carcinoma. The recurrence time of the PN group is shorter than that of the RN group. For patients after PN surgery, median recurrence time is longer for patients with T1a stage tumor when compared with those with stage beyond T1a. Patients can obtain relative long-term survival after complete secondary surgery resection.

Key words: Renal cell carcinoma, Tumor recurrence, Surgical resection

CLC Number: 

  • R737.11

Figure 1

Comparison of the time to recurrence after initial partial nephrectomy an radical nephrectomy"

Figure 2

Comparison of the time to recurrence between patients with T1a stage and beyond T1a stage after initial partial nephrectomy"

[1] Siegel R, Miller K, Jemal A . Cancer statistics, 2018[J]. CA Cancer J Clin, 2018,68(1):7-30.
[2] Kuusk T , Grivas N, de Bruijn R, et al. The current management of renal cell carcinoma[J]. Minerva Med, 2017,108(4):357-369.
[3] Margulis V, Mcdonald M, Tamboli P , et al. Predictors of oncolo-gical outcome after resection of locally recurrent renal cell carcinoma[J]. J Urol, 2009,181(5):2044-2051.
[4] 杨洋, 肖云翔, 周利群 , 等. 手术治疗肾癌根治术后孤立局部复发病灶的长期预后分析[J]. 北京大学学报(医学版), 2014,46(4):528-531.
[5] Lane BR, Gill IS . 5-year outcomes of laparoscopic partial nephrectomy[J]. J Urol, 2007,177(1):70-74.
[6] Campbell SC, Novick AC . Management of local recurrence fol-lowing radical nephrectomy or partial nephrectomy[J]. Urol Clin North Am, 1994,21(4):593-599.
[7] Bigot P, Hetet JF, Bernhard JC , et al. Nephron-sparing surgery for renal tumors measuring more than 7 cm: morbidity, and functional and oncological outcomes[J]. Clin Genitourin Cancer, 2014,12(1):e19-e27.
[8] Mir MC, Derweesh I, Porpiglia F , et al. Partial nephrectomy versus radical nephrectomy for clinical T1b and T2 renal tumors: a systematic review and meta-analysis of comparative studies[J]. Eur Urol, 2017,71(4):606-617.
[9] Brookman-May S, May M, Shariat SF , et al. Features associated with recurrence beyond 5 years after nephrectomy and nephron-sparing surgery for renal cell carcinoma: development and internal validation of a risk model (PRELANE score) to predict late recurrence based on a large multicenter database (CORONA/SATURN Project)[J]. Eur Urol, 2013,64(3):472-477.
[10] Nakano E, Fujioka H, Matsuda M , et al. Late recurrence of renal cell carcinoma after nephrectomy[J]. Eur Urol, 1984,10(5):347-349.
[11] Miyao N, Naito S, Ozono S , et al. Late recurrence of renal cell carcinoma: retrospective and collaborative study of the Japanese Society of Renal Cancer[J]. Urology, 2011,77(2):379-384.
[12] Park YH, Baik KD, Lee YJ , et al. Late recurrence of renal cell carcinoma >5 years after surgery: clinicopathological characteristics and prognosis[J]. BJU Int, 2012,110(11 Pt B):E553-E558.
[13] Lee BH, Feifer A, Feuerstein MA , et al. Validation of a post-operative nomogram predicting recurrence in patients with conventional clear cell renal cell carcinoma[J]. Eur Urol Focus, 2018,4(1):100-105.
[14] Itano NB, Blute ML, Spotts B , et al. Outcome of isolated renal cell carcinoma fossa recurrence after nephrectomy[J]. J Urol, 2000,164(2):322-325.
[15] Yohannan J, Feng T, Berkowitz J , et al. Laparoscopic resection of local recurrence after previous radical nephrectomy for clinically localized renal-cell carcinoma: perioperative outcomes and initial observations[J]. J Endourol, 2010,24(10):1609-1612.
[16] Ljungberg B, Albiges L, Abu-Ghanem Y , et al. European Association of Urology Guidelines on Renal Cell Carcinoma: The 2019 Update[J]. Eur Urol, 2019,75(5):799-810.
[1] Fan SHU,Yichang HAO,Zhanyi ZHANG,Shaohui DENG,Hongxian ZHANG,Lei LIU,Guoliang WANG,Xiaojun TIAN,Lei ZHAO,Lulin MA,Shudong ZHANG. Functional and oncologic outcomes of partial nephrectomy for cystic renal cell carcinoma: A single-center retrospective study [J]. Journal of Peking University (Health Sciences), 2024, 56(4): 667-672.
[2] Zezhen ZHOU,Shaohui DENG,Ye YAN,Fan ZHANG,Yichang HAO,Liyuan GE,Hongxian ZHANG,Guoliang WANG,Shudong ZHANG. Predicting the 3-year tumor-specific survival in patients with T3a non-metastatic renal cell carcinoma [J]. Journal of Peking University (Health Sciences), 2024, 56(4): 673-679.
[3] Yun-chong LIU,Zong-long WU,Li-yuan GE,Tan DU,Ya-qian WU,Yi-meng SONG,Cheng LIU,Lu-lin MA. Mechanism of nuclear protein 1 in the resistance to axitinib in clear cell renal cell carcinoma [J]. Journal of Peking University (Health Sciences), 2023, 55(5): 781-792.
[4] Dong LAN,Zhuo LIU,Yu-xuan LI,Guo-liang WANG,Xiao-jun TIAN,Lu-lin MA,Shu-dong ZHANG,Hong-xian ZHANG. Risk factors for massive hemorrhage after radical nephrectomy and removal of venous tumor thrombus [J]. Journal of Peking University (Health Sciences), 2023, 55(5): 825-832.
[5] Yun-yi XU,Zheng-zheng SU,Lin-mao ZHENG,Meng-ni ZHANG,Jun-ya TAN,Ya-lan YANG,Meng-xin ZHANG,Miao XU,Ni CHEN,Xue-qin CHEN,Qiao ZHOU. Read-through circular RNA rt-circ-HS promotes hypoxia inducible factor 1α expression and renal carcinoma cell proliferation, migration and invasiveness [J]. Journal of Peking University (Health Sciences), 2023, 55(2): 217-227.
[6] Qi SHEN,Yi-xiao LIU,Qun HE. Mucinous tubular and spindle cell carcinoma of kidney: Clinicopathology and prognosis [J]. Journal of Peking University (Health Sciences), 2023, 55(2): 276-282.
[7] Quan ZHANG,Hai-feng SONG,Bing-lei MA,Zhe-nan ZHANG,Chao-hui ZHOU,Ao-lin LI,Jun LIU,Lei LIANG,Shi-yu ZHU,Qian ZHANG. Pre-operative prognostic nutritional index as a predictive factor for prognosis in non-metastatic renal cell carcinoma treated with surgery [J]. Journal of Peking University (Health Sciences), 2023, 55(1): 149-155.
[8] Cai-peng QIN,Yu-xuan SONG,Meng-ting DING,Fei WANG,Jia-xing LIN,Wen-bo YANG,Yi-qing DU,Qing LI,Shi-jun LIU,Tao XU. Establishment of a mutation prediction model for evaluating the efficacy of immunotherapy in renal carcinoma [J]. Journal of Peking University (Health Sciences), 2022, 54(4): 663-668.
[9] Mei-ni ZUO,Yi-qing DU,Lu-ping YU,Xiang DAI,Tao XU. Correlation between metabolic syndrome and prognosis of patients with clear cell renal cell carcinoma [J]. Journal of Peking University (Health Sciences), 2022, 54(4): 636-643.
[10] Tian-yu CAI,Zhen-peng ZHU,Chun-ru XU,Xing JI,Tong-de LV,Zhen-ke GUO,Jian LIN. Expression and significance of fibroblast growth factor receptor 2 in clear cell renal cell carcinoma [J]. Journal of Peking University (Health Sciences), 2022, 54(4): 628-635.
[11] Er-shu BO,Peng HONG,Yu ZHANG,Shao-hui DENG,Li-yuan GE,Min LU,Nan LI,Lu-lin MA,Shu-dong ZHANG. Clinicopathological features and prognostic analysis of papillary renal cell carcinoma [J]. Journal of Peking University (Health Sciences), 2022, 54(4): 615-620.
[12] Yu TIAN,Xiao-yue CHENG,Hui-ying HE,Guo-liang WANG,Lu-lin MA. Clinical and pathological features of renal cell carcinoma with urinary tract tumor thrombus: 6 cases report and literature review [J]. Journal of Peking University (Health Sciences), 2021, 53(5): 928-932.
[13] HONG Peng,TIAN Xiao-jun,ZHAO Xiao-yu,YANG Fei-long,LIU Zhuo,LU Min,ZHAO Lei,MA Lu-lin. Bilateral papillary renal cell carcinoma following kidney transplantation: A case report [J]. Journal of Peking University (Health Sciences), 2021, 53(4): 811-813.
[14] HAN Song-chen,HUANG Zi-xiong,LIU Hui-xin,XU Tao. Renal functional compensation after unilateral radical nephrectomy of renal cell carcinoma [J]. Journal of Peking University (Health Sciences), 2021, 53(4): 680-685.
[15] ZHAO Xun,YAN Ye,HUANG Xiao-juan,DONG Jing-han,LIU Zhuo,ZHANG Hong-xian,LIU Cheng,MA Lu-lin. Influence of deep invasive tumor thrombus on the surgical treatment and prognosis of patients with non-metastatic renal cell carcinoma complicated with venous tumor thrombus [J]. Journal of Peking University (Health Sciences), 2021, 53(4): 665-670.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
No Suggested Reading articles found!